Another company has announced its quarterly results. After the results, the stock has fallen sharply. The stock has fallen by more than 8 percent. The stock has fallen by Rs 150 in a few seconds. At the same time, the stock has given a negative return of 15 percent in one year. The stock has fallen by 40 percent in three years.

Talking about VENKYS India... The company has announced its quarterly results on the exchange. Profit has fallen on an annual basis. In comparison to the July-September quarter of the financial year 2023-24, the profit has fallen by 70% to Rs 8 crore in the July-September quarter of the financial year 2024-25. A year ago the profit was Rs 34 crore. During this period, income has also fallen. It has come down from Rs 913 crore to Rs 774 crore. EBITDA has come down from Rs 50 crore to Rs 14 crore. EBITDA margin has come down from 5.5% to 1.8%. (FIIs Investment: FIIs buying will return in 10 shares - announcement has been made) Alembic Pharma Q2 results have also come.  The company has announced its quarterly results on the exchange. Profit has increased on an annual basis. Compared to the July-September quarter of the financial year 2023-24, the profit has increased from Rs 137 crore to Rs 155 crore in the July-September quarter of the financial year 2024-25. (Shares doubled rapidly after listing, today saw a decline of 8% for the first time) Income has increased from Rs 1595 crore to Rs 1648 crore. EBITDA has increased from Rs 209 crore to Rs 240 crore. EBITDA margin has increased from 13.10% to 14.6%. The company said that there has been a one-time income of Rs 13 crore.